­

About @ccnxc019

This author has not yet filled in any details.
So far @ccnxc019 has created 37 blog entries.

med fusion and GenomOncology Partner to Match Drug and Clinical Trial Options to Patient Tumors

  Lewisville, TX and Cleveland, OH, (October 8, 2014) – med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient’s disease state and tumor profile. The companies believe that GenomOncology’s [...]

October 8th, 2014|

Jon L. Hart Named Chief Executive Officer of med fusion

Lewisville, Texas (April 7, 2014) ― med fusion, an integrated, advanced laboratory and clinical trials service organization, announced today the appointment of Jon L. Hart as chief executive officer, effective March 31. This appointment is the next step in the organization’s continued drive towards becoming the clear leader in providing lab and clinical trial support [...]

April 7th, 2014|

med fusion and Theranostics Health Release Novel Cancer Theranostic Test

TheraLink™ HER Family Assay Provides Guidance for Directing Molecular Targeted Therapies Lewsiville, TX, May 29, 2013 med fusion and Theranostics Health will introduce the first of the TheraLink™ Assays for use in patients with malignant diseases at the American Society of Clinical Oncology (ASCO) Annual '13 Meeting, held in Chicago, IL from May 31, 2013 [...]

May 29th, 2013|

med fusion, Pathologists Bio-Medical Laboratories (PBM) and Theranostics Health to Announce Availability of Novel Cancer Theranostic Test at ASCO

Lewsiville, TX, May 1, 2013 med fusion, Pathologists Bio-Medical Laboratories (PBM) and Theranostics Health will be introducing the first of Theranostics Health’s TheraLink™ Assays for use in patients with malignant diseases at the upcoming American Society of Clinical Oncology (ASCO) Annual ’13 Meeting, held in Chicago, IL from May 30, 2013 through June 4, 2013. [...]

May 1st, 2013|

med fusion clin-labs supports “Choosing Wisely®”, an initiative recently announced by the American Society of Clinical Pathology

med fusion clin-labs supports “Choosing Wisely®”, an initiative recently announced by the American Society of Clinical Pathology (ASCP), urging physicians and patients to engage in important conversations about some medical tests and procedures that may provide little benefit and in some cases actually harm. “Choosing Wisely” means questioning is it the: “right test, right patient, [...]

April 11th, 2013|

med fusion becomes Carter BloodCare Bronze Partner

Based on med fusion's 2012 contribution to Carter BloodCare's community blood supply, we are now considered a Carter BloodCare Bronze Partner. As part of the Premier Partners program, our Bronze status means we have more opportunities for making a difference.

March 1st, 2013|

med fusion Partners with Theranostics Health to Advance Personalized Medicine for Patients with Cancer

Lewsiville, TX, August 15, 2012 med fusion and Theranostics Health have entered into a Market Development Agreement to validate the clinical utility of Theranostics’ TheraLink™ Assays for use in patients with malignant diseases. The goal of this relationship is to help accelerate advancement of new methods in molecular diagnostics testing and their use in personalized [...]

August 15th, 2012|

Roche Diagnostics enters strategic alliance with med fusion that recognizes company as a Roche Molecular Center of Excellence

Indianapolis, June 5, 2012 Collaborative relationship designed to help accelerate advancement of new methods in molecular diagnostics testing and personalized predictive treatment Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the establishment of a strategic alliance with med fusion LLC in Lewisville, Texas, that designates the company as a Roche Molecular Center of Excellence (MCOE) [...]

June 5th, 2012|

The cobas® HPV cervical screening test reports genotypes 16 and 18 concurrently with no additional cost or action needed by the patient or physician

The cobas® HPV test uncovers disease missed by cytology, providing more information about cancer risk in women with normal cytology (NILM) than pooled hrHPV testing alone. Approximately one in 10 women with normal cytology who were HPV 16+ and/or 18+ actually had high-grade cervical disease that was missed with cytology.1 To learn more about the [...]

May 13th, 2012|

med fusion lands large HCA contract

November 8, 2010 Dallas Business Journal med fusion has entered a contract with HCA North Texas to provide lab services for more than 30 HCA hospitals, outpatient surgery centers and other facilities in North Texas. "The agreement gives Dallas-based HCA hospitals immediate, local access to hundreds of complex tests performed by med fusion," CEO Keith [...]

November 8th, 2010|